Table 4.
Baseline | n | 6 Months | n | p | Baseline | n | 12 Months | n | p |
---|---|---|---|---|---|---|---|---|---|
FVC | |||||||||
74.0 (62.5–82.5) | 39 | 73.0 (64.0–84.5) | 31 | 0.469 | 75.0 (64.0–82.5) | 35 | 76.0 (58.0–84.5) | 23 | 0.396 |
FEV1 | |||||||||
81.0 (69.0–94.5) | 35 | 81.0 (67.5–90.5) | 27 | 0.949 | 81.0 (70.0–97.0) | 31 | 75.0 (69.5–86.8) | 18 | 0.055 |
DLCO | |||||||||
43.0 (34.0–60.0) | 37 | 38.0 (31.0–48.8) | 26 | 0.041 | 44.0 (34.0–60.8) | 34 | 42.5 (32.5–57.8) | 22 | 0.048 |
Data are presented as median (IQR). FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; and DLCO: diffusing capacity of the lungs for carbon monoxide. When comparing the measurements at baseline to those at 6 months, the analysis only included individuals who had been on NTD for a minimum of 4 months; when comparing measurements at baseline and at 12 months, only individuals who had been on NTD for at least 9 months were considered.